According to our new research report “Booming US Generic Drug Market”, US represents the most promising pharmaceutical market. The country’s generic drugs market has witnessed healthy growth rate over the past few years. Growth in the generic segment has outpaced growth in the overall pharmaceutical market. The share of generic drugs in the total prescription market has stupendously risen to around 75% in 2009 and is expected to grow further in near future. With the patent expiration of number of key blockbuster drugs in coming years and supportive regulatory framework, the US generic market is projected to grow at a CAGR of around 10% during FY2010-FY2013.
Our research has identified some key factors acting as a catalyst for the generic industry current and future growth outlook in the United States. The report reveals that rapidly aging population and increasing pressure from the insurance firms to cut healthcare cost will give impetus to the US generic market. The report also discusses the potential of generic drugs in key therapeutic segments of the pharmaceutical industry, which gives a clear idea about types of products present and further scope of development in the market.
We have also done an extensive research on the country’s regulatory framework and found that the US government is adopting several measures to support the generic industry as it saves a huge amount for Health Care System annually. We have also covered some of the major prevailing industry trends that will continue to propel the industry in coming years.
Our report “Booming US Generic Drug Market” thoroughly examines the current market trends, industrial developments, government regulations and competitive landscape to enable clients understand the market structure and its progress in coming years. Industry forecast given in the report has been made considering the possible post-recession impact, current scenario and growth opportunities present in the market. In addition, it provides valuable information about the industry to international pharmaceutical & generic players and investors looking to enter the market.
For more information visit: http://www.rncos.com/Report/IM589.htm |
